Clinical Trials · NCT01714843

A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

CompletedPhase 2Linaclotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Astellas Pharma Inc
Enrollment
559
Start date
Aug 2012
Locations
4 sites, Japan
Primary endpoint
Global assessment of relief of IBS symptoms Responder
View Linaclotide compound reference